Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30802535 | 1.00 | TLR2 (0.45) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL25657522 | 1.00 | TLR2 (0.45) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL29854978 | 1.00 | TLR2 (0.45) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL30792938 | 0.99 | TLR2 (0.43) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL119776 | 0.95 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL29398446 | 0.95 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL17810785 | 0.95 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL16095317 | 0.95 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL30564433 | 0.95 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7TNF | |
| SCHEMBL118970 | 0.95 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | claimed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | claimed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023214576-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | TLR2 3821/4885KMT2A 3145/4885FABP5 4094/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | TLR2 3821/4885KMT2A 3145/4885FABP5 4094/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | TLR2 4611/4885KMT2A 4757/4885FABP5 4026/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | TLR2 3821/4885KMT2A 3145/4885FABP5 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.